Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on January 11, 2021, to report preliminary financial information and corporate updates presented at the 39th Annual J.P. Morgan Healthcare Conference. The company provided an update on its key products, notably EYLEA®, with preliminary full-year 2020 U.S. net product sales of approximately $4.95 billion. This reflects approximately $1.34 billion in U.S. net product sales for the fourth quarter of 2020, with distributor inventory levels remaining within the targeted range. Furthermore, the report highlighted significant progress and sales for its novel investigational dual-antibody therapy for COVID-19, casirivimab and imdevimab. Preliminary full-year 2020 U.S. net product sales for this therapy were approximately $184 million, with $144 million attributed to the fourth quarter. Regeneron anticipates fulfilling the remaining 300,000 doses under its contract with the U.S. government by the end of February 2021. Investors should note the preliminary and unaudited nature of these figures, and the forward-looking statements carry inherent risks.
Key Highlights
- 1Preliminary full-year 2020 U.S. net product sales for EYLEA® were approximately $4.95 billion.
- 2Preliminary Q4 2020 U.S. net product sales for EYLEA® reached approximately $1.34 billion.
- 3EYLEA® distributor inventory levels in the U.S. remained within the company's one-to-two-week target range.
- 4Preliminary full-year 2020 U.S. net product sales for COVID-19 antibody therapy (casirivimab and imdevimab) were approximately $184 million.
- 5Preliminary Q4 2020 U.S. net product sales for the COVID-19 antibody therapy were approximately $144 million.
- 6Regeneron expects to fulfill the remaining 300,000 doses of its COVID-19 antibody therapy under the U.S. government contract by the end of February 2021.